A recent study reveals that patients who stop using popular GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds much more quickly than those who end conventional lifestyle plans.
Research printed in a major health publication points out that while obese people can lose substantial amounts of their total mass while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month after stopping.
"People buying such treatments must be aware of the danger of fast weight regain when the medication concludes," stated researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting weight within about a year and a half.
Weighing Therapies
The study, which reviewed 37 of trials involving over 9,000 of patients, contrasted the results of the injectable medications with older methods.
The team point out that people who shed pounds through lifestyle changes alone usually experience a slower creep back—around 100 grams monthly—after stopping.
Understanding the Rapid Regain
Nutrition scientists suggest the way of the jabs explains the heightened regain.
The injections imitate a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 levels several times higher than normal may cause the system to produce less of its endogenous GLP-1, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' means appetite is no longer kept in check, making excessive eating much more probable."
An Ongoing Condition?
The NHS suggest the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
Many experts contend that, considering the significant potential of relapse, the therapy is often life-long.
This view is supported by drug manufacturers, who state that the findings "highlight the chronic character of obesity," comparing it to managing diseases like high blood pressure.
Patient Testimonies
Users who have discontinued the medication report a intense resurgence of cravings.
"I experienced a trigger flipping and I was suddenly starving," described a patient.
This challenge is compounded if individuals have not developed lasting dietary or behavioural changes during therapy.
Significant Interest
Figures suggest that millions of adults in the UK have tried these injections in the past year, with desire continuing to grow.
- Use is more common among females than men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Ultimately, clinicians emphasize that while the jabs are powerful tools for shedding pounds, they are not a standalone solution and lasting health benefits relies on ongoing behavioural support.
